Adipose-derived mesenchymal stem cell therapy for connective tissue diseases and complications
Mesenchymal stem cells (MSCs) may be effective in treating connective tissue disease and associated organ damage, leveraging their anti-inflammatory and immunoregulatory effects. Moreover, MSCs may possess the ability to produce antiapoptotic, proliferative, growth, angiogenic, and antifibrotic fact...
Gespeichert in:
| Veröffentlicht in: | Inflammation and Regeneration 2024-07, Vol.44 (1), p.35-23, Article 35 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 23 |
|---|---|
| container_issue | 1 |
| container_start_page | 35 |
| container_title | Inflammation and Regeneration |
| container_volume | 44 |
| creator | Kotani, Takuya Saito, Takashi Suzuka, Takayasu Matsuda, Shogo |
| description | Mesenchymal stem cells (MSCs) may be effective in treating connective tissue disease and associated organ damage, leveraging their anti-inflammatory and immunoregulatory effects. Moreover, MSCs may possess the ability to produce antiapoptotic, proliferative, growth, angiogenic, and antifibrotic factors. Among MSCs, adipose-derived MSCs (ASCs) stand out for their relative ease of harvesting and abundance. Additionally, studies have indicated that compared with bone marrow-derived MSCs, ASCs have superior immunomodulatory, proangiogenic, antiapoptotic, and antioxidative properties. However, relatively few reviews have focused on the efficacy of ASC therapy in treating connective tissue disease (CTD) and interstitial lung disease (ILD). Therefore, this review aims to evaluate evidence from preclinical studies that investigate the effectiveness of MSC therapy, specifically ASC therapy, in managing CTD and ILD. Moreover, we explore the outcomes of documented clinical trials. We also introduce an innovative approach involving the utilization of pharmacologically primed ASCs in the CTD model to address the current challenges associated with ASC therapy. |
| doi_str_mv | 10.1186/s41232-024-00348-z |
| format | Article |
| fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11264739</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A801883757</galeid><doaj_id>oai_doaj_org_article_303e945bf04f4f38ba1866eb6e9d3eca</doaj_id><sourcerecordid>A801883757</sourcerecordid><originalsourceid>FETCH-LOGICAL-c417t-2e9ea02d1b6596af021c8661ae51d6a37541beb61b84b278c6476ee3baec9a0e3</originalsourceid><addsrcrecordid>eNpVUk1r3DAQNaWlCWn-QA_Fx16c6MOWpVNZQj8CgV7aa8VYGu8q2JYreQObX9_ZeBMa6SAxM-_x9PSK4iNnV5xrdZ1rLqSomKgrxmStq8c3xTnXmlWaG_b2dDfKyLPiMud7RqtRTcPN--JMGiaUaJvz4s_GhzlmrDym8IC-HDHj5HaHEYYyLziWDoehXHaYYD6UfUyli9OEbqHpcgk577H0ISNkzCVMntrjPAQHS4hT_lC862HIeHk6L4rf377-uvlR3f38fnuzuatczdulEmgQmPC8U41R0DPBnVaKAzbcK5BtU_MOO8U7XXei1U7VrUKUHaAzwFBeFLcrr49wb-cURkgHGyHYp0JMWwtpCW5AK5lEUzddz-q-7qXugOxURI7GS3RAXF9WrnnfjegdTkuC4RXp684UdnYbHyzngnRJQwyfTwwp_t1jXuwY8tFHmDDuM0nQZL_RrKXRq3V0C6QtTH0kSkfb4xjIaewD1Tea0XeSDUeAWAEuxZwT9i_COLPHZNg1GZaSYZ-SYR8J9On_J71AnnMg_wGQ5bbH</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3082629807</pqid></control><display><type>article</type><title>Adipose-derived mesenchymal stem cell therapy for connective tissue diseases and complications</title><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>Springer Nature OA Free Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>SpringerLink Journals - AutoHoldings</source><creator>Kotani, Takuya ; Saito, Takashi ; Suzuka, Takayasu ; Matsuda, Shogo</creator><creatorcontrib>Kotani, Takuya ; Saito, Takashi ; Suzuka, Takayasu ; Matsuda, Shogo</creatorcontrib><description>Mesenchymal stem cells (MSCs) may be effective in treating connective tissue disease and associated organ damage, leveraging their anti-inflammatory and immunoregulatory effects. Moreover, MSCs may possess the ability to produce antiapoptotic, proliferative, growth, angiogenic, and antifibrotic factors. Among MSCs, adipose-derived MSCs (ASCs) stand out for their relative ease of harvesting and abundance. Additionally, studies have indicated that compared with bone marrow-derived MSCs, ASCs have superior immunomodulatory, proangiogenic, antiapoptotic, and antioxidative properties. However, relatively few reviews have focused on the efficacy of ASC therapy in treating connective tissue disease (CTD) and interstitial lung disease (ILD). Therefore, this review aims to evaluate evidence from preclinical studies that investigate the effectiveness of MSC therapy, specifically ASC therapy, in managing CTD and ILD. Moreover, we explore the outcomes of documented clinical trials. We also introduce an innovative approach involving the utilization of pharmacologically primed ASCs in the CTD model to address the current challenges associated with ASC therapy.</description><identifier>ISSN: 1880-9693</identifier><identifier>ISSN: 1880-8190</identifier><identifier>EISSN: 1880-8190</identifier><identifier>DOI: 10.1186/s41232-024-00348-z</identifier><identifier>PMID: 39026275</identifier><language>eng</language><publisher>England: Springer</publisher><subject>Adipose-derived stem cells ; Analysis ; B cells ; Belimumab ; Complications and side effects ; Connective tissue disease ; Development and progression ; Interstitial lung disease ; Lung diseases ; Mesenchymal stem cells ; Review ; Stem cells ; Transplantation</subject><ispartof>Inflammation and Regeneration, 2024-07, Vol.44 (1), p.35-23, Article 35</ispartof><rights>2024. The Author(s).</rights><rights>COPYRIGHT 2024 Springer</rights><rights>The Author(s) 2024 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c417t-2e9ea02d1b6596af021c8661ae51d6a37541beb61b84b278c6476ee3baec9a0e3</cites><orcidid>0000-0003-2190-0780</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11264739/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11264739/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39026275$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kotani, Takuya</creatorcontrib><creatorcontrib>Saito, Takashi</creatorcontrib><creatorcontrib>Suzuka, Takayasu</creatorcontrib><creatorcontrib>Matsuda, Shogo</creatorcontrib><title>Adipose-derived mesenchymal stem cell therapy for connective tissue diseases and complications</title><title>Inflammation and Regeneration</title><addtitle>Inflamm Regen</addtitle><description>Mesenchymal stem cells (MSCs) may be effective in treating connective tissue disease and associated organ damage, leveraging their anti-inflammatory and immunoregulatory effects. Moreover, MSCs may possess the ability to produce antiapoptotic, proliferative, growth, angiogenic, and antifibrotic factors. Among MSCs, adipose-derived MSCs (ASCs) stand out for their relative ease of harvesting and abundance. Additionally, studies have indicated that compared with bone marrow-derived MSCs, ASCs have superior immunomodulatory, proangiogenic, antiapoptotic, and antioxidative properties. However, relatively few reviews have focused on the efficacy of ASC therapy in treating connective tissue disease (CTD) and interstitial lung disease (ILD). Therefore, this review aims to evaluate evidence from preclinical studies that investigate the effectiveness of MSC therapy, specifically ASC therapy, in managing CTD and ILD. Moreover, we explore the outcomes of documented clinical trials. We also introduce an innovative approach involving the utilization of pharmacologically primed ASCs in the CTD model to address the current challenges associated with ASC therapy.</description><subject>Adipose-derived stem cells</subject><subject>Analysis</subject><subject>B cells</subject><subject>Belimumab</subject><subject>Complications and side effects</subject><subject>Connective tissue disease</subject><subject>Development and progression</subject><subject>Interstitial lung disease</subject><subject>Lung diseases</subject><subject>Mesenchymal stem cells</subject><subject>Review</subject><subject>Stem cells</subject><subject>Transplantation</subject><issn>1880-9693</issn><issn>1880-8190</issn><issn>1880-8190</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVUk1r3DAQNaWlCWn-QA_Fx16c6MOWpVNZQj8CgV7aa8VYGu8q2JYreQObX9_ZeBMa6SAxM-_x9PSK4iNnV5xrdZ1rLqSomKgrxmStq8c3xTnXmlWaG_b2dDfKyLPiMud7RqtRTcPN--JMGiaUaJvz4s_GhzlmrDym8IC-HDHj5HaHEYYyLziWDoehXHaYYD6UfUyli9OEbqHpcgk577H0ISNkzCVMntrjPAQHS4hT_lC862HIeHk6L4rf377-uvlR3f38fnuzuatczdulEmgQmPC8U41R0DPBnVaKAzbcK5BtU_MOO8U7XXei1U7VrUKUHaAzwFBeFLcrr49wb-cURkgHGyHYp0JMWwtpCW5AK5lEUzddz-q-7qXugOxURI7GS3RAXF9WrnnfjegdTkuC4RXp684UdnYbHyzngnRJQwyfTwwp_t1jXuwY8tFHmDDuM0nQZL_RrKXRq3V0C6QtTH0kSkfb4xjIaewD1Tea0XeSDUeAWAEuxZwT9i_COLPHZNg1GZaSYZ-SYR8J9On_J71AnnMg_wGQ5bbH</recordid><startdate>20240719</startdate><enddate>20240719</enddate><creator>Kotani, Takuya</creator><creator>Saito, Takashi</creator><creator>Suzuka, Takayasu</creator><creator>Matsuda, Shogo</creator><general>Springer</general><general>BioMed Central</general><general>BMC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IAO</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-2190-0780</orcidid></search><sort><creationdate>20240719</creationdate><title>Adipose-derived mesenchymal stem cell therapy for connective tissue diseases and complications</title><author>Kotani, Takuya ; Saito, Takashi ; Suzuka, Takayasu ; Matsuda, Shogo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c417t-2e9ea02d1b6596af021c8661ae51d6a37541beb61b84b278c6476ee3baec9a0e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adipose-derived stem cells</topic><topic>Analysis</topic><topic>B cells</topic><topic>Belimumab</topic><topic>Complications and side effects</topic><topic>Connective tissue disease</topic><topic>Development and progression</topic><topic>Interstitial lung disease</topic><topic>Lung diseases</topic><topic>Mesenchymal stem cells</topic><topic>Review</topic><topic>Stem cells</topic><topic>Transplantation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kotani, Takuya</creatorcontrib><creatorcontrib>Saito, Takashi</creatorcontrib><creatorcontrib>Suzuka, Takayasu</creatorcontrib><creatorcontrib>Matsuda, Shogo</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale Academic OneFile</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Inflammation and Regeneration</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kotani, Takuya</au><au>Saito, Takashi</au><au>Suzuka, Takayasu</au><au>Matsuda, Shogo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adipose-derived mesenchymal stem cell therapy for connective tissue diseases and complications</atitle><jtitle>Inflammation and Regeneration</jtitle><addtitle>Inflamm Regen</addtitle><date>2024-07-19</date><risdate>2024</risdate><volume>44</volume><issue>1</issue><spage>35</spage><epage>23</epage><pages>35-23</pages><artnum>35</artnum><issn>1880-9693</issn><issn>1880-8190</issn><eissn>1880-8190</eissn><abstract>Mesenchymal stem cells (MSCs) may be effective in treating connective tissue disease and associated organ damage, leveraging their anti-inflammatory and immunoregulatory effects. Moreover, MSCs may possess the ability to produce antiapoptotic, proliferative, growth, angiogenic, and antifibrotic factors. Among MSCs, adipose-derived MSCs (ASCs) stand out for their relative ease of harvesting and abundance. Additionally, studies have indicated that compared with bone marrow-derived MSCs, ASCs have superior immunomodulatory, proangiogenic, antiapoptotic, and antioxidative properties. However, relatively few reviews have focused on the efficacy of ASC therapy in treating connective tissue disease (CTD) and interstitial lung disease (ILD). Therefore, this review aims to evaluate evidence from preclinical studies that investigate the effectiveness of MSC therapy, specifically ASC therapy, in managing CTD and ILD. Moreover, we explore the outcomes of documented clinical trials. We also introduce an innovative approach involving the utilization of pharmacologically primed ASCs in the CTD model to address the current challenges associated with ASC therapy.</abstract><cop>England</cop><pub>Springer</pub><pmid>39026275</pmid><doi>10.1186/s41232-024-00348-z</doi><tpages>23</tpages><orcidid>https://orcid.org/0000-0003-2190-0780</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1880-9693 |
| ispartof | Inflammation and Regeneration, 2024-07, Vol.44 (1), p.35-23, Article 35 |
| issn | 1880-9693 1880-8190 1880-8190 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11264739 |
| source | DOAJ Directory of Open Access Journals; PubMed Central Open Access; Springer Nature OA Free Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection; SpringerLink Journals - AutoHoldings |
| subjects | Adipose-derived stem cells Analysis B cells Belimumab Complications and side effects Connective tissue disease Development and progression Interstitial lung disease Lung diseases Mesenchymal stem cells Review Stem cells Transplantation |
| title | Adipose-derived mesenchymal stem cell therapy for connective tissue diseases and complications |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T20%3A41%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adipose-derived%20mesenchymal%20stem%20cell%20therapy%20for%20connective%20tissue%20diseases%20and%20complications&rft.jtitle=Inflammation%20and%20Regeneration&rft.au=Kotani,%20Takuya&rft.date=2024-07-19&rft.volume=44&rft.issue=1&rft.spage=35&rft.epage=23&rft.pages=35-23&rft.artnum=35&rft.issn=1880-9693&rft.eissn=1880-8190&rft_id=info:doi/10.1186/s41232-024-00348-z&rft_dat=%3Cgale_doaj_%3EA801883757%3C/gale_doaj_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3082629807&rft_id=info:pmid/39026275&rft_galeid=A801883757&rft_doaj_id=oai_doaj_org_article_303e945bf04f4f38ba1866eb6e9d3eca&rfr_iscdi=true |